Risk Management for Biotech Companies in Clinical Trials

When we discuss risk, it’s often focused on the negative threats where there is a need to mitigate or avoid threats to the project that could impact timelines, deliverables or quality. One can look at risk as simply uncertainty. From that view, risk can also represent positive opportunities to improve the speed of delivery for certain aspects of the study, or perhaps even cost savings or efficiencies.



  • Alexander Watt, Global Head, Q2 Solutions Biotech
  • Alan Wookey, B.Sc., Scientific Advisor, Oncology, Q2 Solutions


Complete the form below to access this insight brief